MSDC-0602 potassium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534800

CAS#: 1314533-27-1

Description: MSDC-0602 potassium is a bioactive chemical.

Chemical Structure

MSDC-0602 potassium
CAS# 1314533-27-1

Theoretical Analysis

MedKoo Cat#: 534800
Name: MSDC-0602 potassium
CAS#: 1314533-27-1
Chemical Formula: C19H16KNO5S
Exact Mass: 409.0386
Molecular Weight: 409.4973
Elemental Analysis: C, 55.73; H, 3.94; K, 9.55; N, 3.42; O, 19.53; S, 7.83

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MSDC-0602 potassium; MSDC-0602; MSDC 0602; MSDC0602

IUPAC/Chemical Name: 2,4-Thiazolidinedione, 5-((4-(2-(3-methoxyphenyl)-2-oxoethoxy)phenyl)methyl)-, potassium salt (1:1)


InChi Code: InChI=1S/C19H17NO5S.K/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17;/h2-8,10,17H,9,11H2,1H3,(H,20,22,23);/q;+1/p-1

SMILES Code: O=C([N-]1)SC(CC2=CC=C(OCC(C3=CC=CC(OC)=C3)=O)C=C2)C1=O.[K+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 409.4973 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2017 May;65(5):1543-1556. doi: 10.1002/hep.29025. Epub 2017 Mar 30. PMID: 28027586; PMCID: PMC5397348.

2: Colca JR, McDonald WG, Adams WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27(7):631-636. doi: 10.1080/13543784.2018.1494153. Epub 2018 Jul 17. PMID: 29950116.

3: Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res. 2015 Mar;30(3):481-8. doi: 10.1002/jbmr.2364. PMID: 25257948; PMCID: PMC4472363.

4: Vigueira PA, McCommis KS, Hodges WT, Schweitzer GG, Cole SL, Oonthonpan L, Taylor EB, McDonald WG, Kletzien RF, Colca JR, Finck BN. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol. 2017 Aug 1;102(8):985-999. doi: 10.1113/EP086380. Epub 2017 Jul 10. PMID: 28597936; PMCID: PMC5667918.

5: Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, Qi N, McDonald WG, Colca JR, Kletzien RF, Finck BN. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. doi: 10.1074/jbc.M112.363960. Epub 2012 May 23. PMID: 22621923; PMCID: PMC3390629.

6: Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020 Mar 6:154203. doi: 10.1016/j.metabol.2020.154203. Epub ahead of print. PMID: 32151660.

7: Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, Wolfe CL, Wheeler JS, Coulter KR, Kilkuskie PM, Gracheva E, Korshunova Y, Trusgnich M, Karr R, Wiley SE, Divakaruni AS, Murphy AN, Vigueira PA, Finck BN, Kletzien RF. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One. 2013 May 15;8(5):e61551. doi: 10.1371/journal.pone.0061551. PMID: 23690925; PMCID: PMC3655167.